Datasets
Buyer room
LOSELAB.COMManage supplier listing
LoseLab (published by MonacoWebPix) — Normalized manufacturer cash-pay (self-pay) GLP-1 price index: a monthly time series of Wegovy, Zepbound and Ozempic maintenance-dose self-pay prices expressed as an index (base 100 = Aug 2025, reading 76.6 in Sep 2026, i.e. -23%), underpinned by a price-change event ledger where every change carries effective date, drug, self-pay price, dose range and conditionality (e.g. refill within 45 days) plus a link to the manufacturer announcement that caused it — alongside per-drug cash-price pages, an overpayment checker keyed to dose/pharmacy/ZIP, and a provid…
supplier index read from their site
Normalized manufacturer cash-pay (self-pay) GLP-1 price index: a monthly time series of Wegovy, Zepbound and Ozempic maintenance-dose self-pay prices expressed as an index (base 100 = Aug 2025, reading 76.6 in Sep 2026, i.e. -23%), underpinned by a price-change event ledger where every change carries effective date, drug, self-pay price, dose range and conditionality (e.g. refill within 45 days) plus a link to the manufacturer announcement that caused it — alongside per-drug cash-price pages, an overpayment checker keyed to dose/pharmacy/ZIP, and a provider legal-risk tracker.
From 2 yearsAsset class EquitiesTickers LLY · NVO · NVO.CO
Sample, licence terms, pricing and eval results when Loselab publishes them. Until then, discover alternatives today with a 7-day trial.
Start 7-day trial →What buyers ask about Loselab, answered from this page.
LoseLab (published by MonacoWebPix) — Normalized manufacturer cash-pay (self-pay) GLP-1 price index: a monthly time series of Wegovy, Zepbound and Ozempic maintenance-dose self-pay prices expressed as an index (base 100 = Aug 2025, reading 76.6 in Sep 2026, i.e. -23%), underpinned by a price-change event ledger where every change carries effective date, drug, self-pay price, dose range and conditionality (e.g. refill within 45 days) plus a link to the manufacturer announcement that caused it — alongside per-drug cash-price pages, an overpayment checker keyed to dose/pharmacy/ZIP, and a provid…
Loselab offers (Alternative, Price, Reference) — Index series: ~13-25 monthly normalized points across 3 drugs (~40-75 data points after the Sept 2026 correction pruned unsourced pre-2026 entries). Change ledger: 7-plus sourced price events on one page, each with effective date, drug, price, dose range, conditionality and announcement URL, replicated across per-drug cost pages. Adjacent assets add a five-dimension product scorecard (effectiveness, safety, value, accessibility, user experience applied to every reviewed product), a provider legal-risk tracker, and the dose/pharmacy/ZIP route table behind the checker. On the order of 150-400 sourced observations site-wide..
Longitudinal tracking of manufacturer direct-to-consumer cash pricing as it decouples from list price (the site's own thesis: list prices barely moved while manufacturer cash programs fell 23%); event studies anchored to dated manufacturer announcements; dose-tier price-elasticity analysis; payer and employer benchmarking of cash-pay versus insured pathways; manufacturer self-pay strategy monitoring for competitors of Novo Nordisk and Lilly; downstream valuation input for telehealth operators whose compounded pricing must undercut these cash floors; consumer-overpayment estimation by dose/pharmacy/ZIP; and the provider legal-risk tracker as a counterparty/compliance screening input.
The data is with 2 years of history.
Coverage spans US, Other; Pharmaceuticals, Health Care Facilities; alternative, price, reference; equities.
Loselab has not added their own details yet. Not yet on file: